Regular Check-Ups Provide Necessary Support During Breast Cancer Survivorship
Regular check-ups and mammograms are crucial for breast cancer survivors, but there are other aspects of follow-up care that are ...
Tag: ESMO Congress
Fertility Preservation Options for Young Patients With Breast Cancer
For patients with breast cancer, especially those who are young, discussions around fertility preservation — if they choose to go ...
Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma
Keytruda (pembrolizumab) continued to improve survival versus Yervoy (ipilimumab) in patients with unresectable stage 3 or 4 melanoma, as demonstrated ...
Anti-PD-L1 Antibody Drug Combo May Improve Outcomes in Advanced Kidney Cancer
Anti–PD-L1 monoclonal antibody benmelstobart plus anlotinib for the frontline treatment of advanced renal cell carcinoma (RCC), a type of kidney ...
Lower Keytruda Doses May Be as Effective as Standard Doses for Stage 4 NSCLC
Patients with stage 4 non-small cell lung cancer (NSCLC) treated with either a standard or reduced dose of Keytruda (pembrolizumab) ...
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset
Patients receiving Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-positive metastatic breast cancer showed “remarkable” outcomes, although it may have different side effects ...
Cediranib Added to Lynparza Didn’t Improve Progression, Survival in Ovarian Cancer
Among patients with relapsed platinum-sensitive ovarian cancer, maintenance therapy with Lynparza (olaparbib) plus cediranib did not result in significant improvements ...
Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma
Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the ...
Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma
Patients with high-risk muscle-invasive urothelial carcinoma (MIUC) who underwent radical surgery experienced notable improvements in disease-free survival (DFS, the time ...
Braftovi Regimen Is Promising in Metastatic Colorectal Cancer
A treatment combination of Braftovi (encorafenib), Erbitux (cetuximab) and chemotherapy showed promising anti-tumor activity in patients with BRAF V600E-mutant metastatic ...
Cyramza Plus Lonsurf Did Not Improve Survival in Metastatic Colorectal Cancer
Overall survival did not improve with Cyramza plus Lonsurf, compared with Lonsurf alonh Lonsurf alone, e, in patients with heavily ...
Rybrevant Plus Chemo Results in Superior Outcomes in EGFR-Mutant Advanced NSCLC
A new study finds that the combination of Rybrevant and chemotherapy improves overall survival in patients with EGFR-mutant advanced non-small ...